Phase 3 study of cladribine with and without cyclophosphamide versus CVP
| Study/arm, doses . | Histology, % . | Response, % . | 3-y PFS, % . | ||
|---|---|---|---|---|---|
| Follicular . | Nonfollicular . | OR . | CR . | ||
| Kalinka-Warzocha et al (2008)61 | 28 | 72 | |||
| CdA | 24 | 76 | 64 (P = .002) | 22 (P = .003) | 48 |
| CCdA | 37 | 63 | 76 (P < .001) | 46 (P < .001) | 61 (P < .001) |
| CVP | 22 | 78 | 44 | 6.7 | 22 |
| Study/arm, doses . | Histology, % . | Response, % . | 3-y PFS, % . | ||
|---|---|---|---|---|---|
| Follicular . | Nonfollicular . | OR . | CR . | ||
| Kalinka-Warzocha et al (2008)61 | 28 | 72 | |||
| CdA | 24 | 76 | 64 (P = .002) | 22 (P = .003) | 48 |
| CCdA | 37 | 63 | 76 (P < .001) | 46 (P < .001) | 61 (P < .001) |
| CVP | 22 | 78 | 44 | 6.7 | 22 |
CdA indicates cladribine at 0.12 mg/kg per day as 2-hour intravenous infusion for 5 consecutive days; CCdA, same cladribine plus cyclophosphamide 800 mg/m2 bolus intravenous every 28 days; and CVP, cyclophosphamide 800 mg/m2 bolus intravenous day 1, vincristine 1.4 mg/m2 bolus intravenous day 1, prednisone 45 mg/m2 PO days 1 to 4 every 21 days.